179386-43-7

Basic information

• Product Name: Sumanirole maleate
• Synonyms: (5R)-5,6-Dihydro-5-(MethylaMino)-4H-iMidazo[4,5,1-ij]quinolin-2(1H)-one (2Z)-2-Butenedioate;(R)-5,6-Dihydro-5-(MethylaMino)-4H-iMidazo[4,5,1-ij]quinolin- 2(1H)-one (2Z)-2-Butenedioate;(R)-5-(MethylaMino)-5,6-dihydro-1H-iMidazo[4,5,1-ij]quinolin-2(4H)-one Maleate,(free base);4H-IMidazo[4,5,1-ij]quinolin-2(1H)-one,5,6-dihydro-5-(MethylaMino)-, (5R)-;(5R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one;Sumanirole
• CAS NO: 179386-43-7
• Molecular Formula: C₁₁H₁₃N₃O
• Molecular Weight: 319.31258
• Mol File: 179386-43-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.32
• Refractive Index: 1.666
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Sumanirole maleate(CAS DataBase Reference)
• NIST Chemistry Reference: Sumanirole maleate(179386-43-7)
• EPA Substance Registry System: Sumanirole maleate(179386-43-7)

Safety Data

• Hazardous Substances Data: 179386-43-7(Hazardous Substances Data)

Usage

Description

Sumanirole maleate is a high affinity D2 receptor agonist, characterized by its off-white to light beige solid appearance. It demonstrates a significant selectivity for the D2 receptor, with over 200-fold selectivity against other dopamine receptor subtypes. Sumanirole exhibits anti-Parkinsonian activity comparable to Ropinirole (R641000), making it a promising compound for the treatment of Parkinson's disease and other related conditions.

Uses

Used in Pharmaceutical Industry:
Sumanirole maleate is used as a therapeutic agent for the treatment of Parkinson's disease. Its high affinity for the D2 receptor and selectivity against other dopamine receptor subtypes contribute to its effectiveness in managing the symptoms of the disease.
Additionally, due to its anti-Parkinsonian activity, Sumanirole maleate may also be used as a research tool in the development of new treatments for other movement disorders and neurodegenerative conditions related to dopamine receptor dysregulation.
Used in Research and Development:
Sumanirole maleate serves as a valuable compound in the field of neuroscience research, particularly in the study of dopamine receptor function and the development of novel drugs targeting these receptors. Its high selectivity and affinity for the D2 receptor make it an ideal candidate for investigating the role of this receptor subtype in various neurological and psychiatric disorders.

InChI:InChI=1/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1

Upstream product

• 185943-25-3 (R)-5-(Benzyl-methyl-amino)-5,6-dihydro-1H,4H-imidazo[4,5,1-ij]quinolin-2-one 
• 222415-94-3 ((R)-1-Methoxy-2-oxo-1,2,5,6-tetrahydro-4H-imidazo[4,5,1-ij]quinolin-5-yl)-methyl-carbamic acid benzyl ester 
• 166742-98-9 (R)-methyl-(1,2,3,4-tetrahydro-3-quinolinyl)carbamic acid, phenylmethyl ester 
• 166742-99-0 ((R)-1-Methoxycarbamoyl-1,2,3,4-tetrahydro-quinolin-3-yl)-methyl-carbamic acid benzyl ester 
• 166742-97-8 (R)-3-Methylamino-1,2,3,4-tetrahydroquinoline maleate 
• 91-22-5 quinoline 
• 612-18-0 1,2-dihydroquinoline 
• 152400-16-3 1-tert-butyloxycarbonyl-1,2-dihydroquinoline 
• 185943-10-6 (1aS,7bR)-1-Methyl-1,1a,2,7b-tetrahydro-1,3-diaza-cyclopropa[a]naphthalene-3-carboxylic acid tert-butyl ester 
• 185943-13-9 (R)-3-Methylamino-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 185943-08-2 (1aR,7bS)-1a,7b-Dihydro-2H-1-oxa-3-aza-cyclopropa[a]naphthalene-3-carboxylic acid tert-butyl ester 
• 185943-04-8 (3R,4R)-3-Hydroxy-4-methylamino-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 185943-17-3 (R)-3-(Benzyl-methyl-amino)-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 
• 185943-22-0 (R)-8-Amino-3-(benzyl-methyl-amino)-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Experiences with commercial production scale operation of dissolving metal reduction using lithium metal and liquid ammonia

The final step which generates free base in the synthesis of Sumanirole Maleate (PNU-95666E) consists of a cryogenic dissolving metal reduction using lithium metal and liquid ammonia. This chemistry was new to the Pfizer API production plant. Due to the hazards associated with the handling of lithium metal and ammonia gas at cryogenic reaction temperature, special challenges were encountered related to the design of the equipment, choice and handling of materials, operations, waste treatment, and both safety and economic issues. The topics discussed in this article include the use of Li instead of Na or K, impact of the choice of physical form of lithium metal, design of the lithium addition apparatus, and problems experienced during the addition. We also discuss techniques for addition of ammonia to the reactor, evaporation of ammonia from the reaction mixture, options for ammonia disposal, and internal reuse of ammonia. Comments on hazards for this reaction are also provided. It is hoped that this document will be of benefit to other professionals who may want to develop and scale-up dissolving metal reduction processes.

Enantioselective synthesis of (R)-Sumanirole using organocatalytic asymmetric aziridination of an α,β-unsaturated aldehyde

Herein we report an enantioselective synthesis of (R)-Sumanirole wherein an organocatalytic asymmetric aziridination of 2-nitrocinnamaldehyde was the key step.

Synthesis of the Selective D2 Receptor Agonist PNU-95666E from D-Phenylalanine Using a Sequential Oxidative Cyclization Strategy

Compound 1 (PNU-95666E) is a selective and high-affinity agonist at the dopamine D2 receptor subtype and is of interest as a potential agent for the treatment of Parkinson's disease. Requiring a synthetic route amenable to scale-up, a synthesis